Pharmaceuticals News

KUALA LUMPUR, Malaysia, April 13, 2026 (GLOBE NEWSWIRE) -- CUKTECH, peneraju global dalam penyelesaian kuasa pintar, hari ini mengumumkan pelancaran rasmi produk utamanya yang sangat dinantikan di...

KUALA LUMPUR, Malaysia, April 13, 2026 (GLOBE NEWSWIRE) -- CUKTECH, a global leader in intelligent power solutions, today announced the official Malaysian launch of its highly anticipated flagship:...

CAMBRIDGE, Royaume-Uni et MONTRÉAL, 13 avr. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique spécialisée dans l'immunothérapie contre le cancer qui développe des immunothérapies à...

CAMBRIDGE, United Kingdom and MONTREAL, April 13, 2026 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies...

LENZELTA® is a new vaccine significantly reducing the incidence and severity of clinical mastitis in vaccinated cows and heifers1. Administration is simple with two doses during the dry-off...

KØBENHAVN, Danmark, 13. april 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 12. marts 2026, hvorunder selskabet vil...

COPENHAGEN, Denmark, April 13, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on March 12, 2026, under which the Company will repurchase shares...

TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically...

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.1This minimally invasive blood test enables...

Dupixent de Sanofi et Regeneron approuvé dans l'UE comme premier médicament ciblé contre l'urticaire chronique spontanée chez les jeunes enfants L'approbation dans l'urticaire chronique spontanée...